Close Menu

Despite having seven employees who all work from home, FerroKin Biosciences plans to bring a drug to market in 2015, reports The Atlantic's Quinn Norton. This low overhead model, Norton adds, allows the companies to focus on nice drugs, and the one FerroKin is developing is to treat congenital anemias.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.